| Drug Name |
Molnupiravir |
| Drug ID |
BADD_D02574 |
| Description |
Molnupiravir (EIDD-2801, MK-4482) is the isopropylester prodrug of [N4-hydroxycytidine].[A193014,A193026] With improved oral bioavailability in non human primates, it is hydrolyzed _in vivo_, and distributes into tissues where it becomes the active 5’-triphosphate form.[A193026] The active drug incorporates into the genome of RNA viruses, leading to an accumulation of mutations known as viral error catastrophe.[A193029] Recent studies have shown molnupiravir inhibits replication of human and bat coronaviruses, including SARS-CoV-2, in mice and human airway epithelial cells.[A193014] A [remdesivir] resistant mutant mouse hepatitis virus has also been shown to have increased sensitivity to N4-hydroxycytidine.[A193014]
Molnupiravir was granted approval by the UK's Medicines and Health products Regulatory Agency (MHRA) on 4 November 2021.[L39050] |
| Indications and Usage |
[N4-hydroxycytidine] and its prodrug molnupiravir are being studied for its activity against a number of viral infections including influenza, MERS-CoV, and SARS-CoV-2.[A193014, A193029]
Molnupiravir is approved in the UK for reducing the risk of hospitalization and death in mild to moderate COVID-19 cases for patients at increased risk of severe disease (eg. with obesity, diabetes mellitus, heart disease, or are over 60 years old).[L39050,L39055] |
| Marketing Status |
investigational |
| ATC Code |
J05AB18 |
| DrugBank ID |
DB15661
|
| KEGG ID |
D11943
|
| MeSH ID |
C000656703
|
| PubChem ID |
145996610
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
0006-5055; 59285-040; 73435-018; 14501-0106; 53922-0137; 62331-063; 66406-0332; 80397-101; 67651-0365; 50683-0596 |
| UNII |
YA84KI1VEW
|
| Synonyms |
molnupiravir | ((2R,3S,4R,5R)-3,4-dihydroxy-5-((4Z)-4-(hydroxyimino)-2-oxo-3,4- dihydropyrimidin-1(2H)-yl)oxolan-2-yl)methyl 2-methylpropanoate | Lagevrio | EIDD-2801 | MK-4482 |
